List of Naftin drug patents

Naftin is owned by Sebela Ireland Ltd.

Naftin contains Naftifine Hydrochloride.

Naftin has a total of 6 drug patents out of which 0 drug patents have expired.

Naftin was authorised for market use on 27 June, 2013.

Naftin is available in gel;topical dosage forms.

Naftin can be used as treatment of fungal infections.

The generics of Naftin are possible to be released after 31 January, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778365 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(9 years from now)

US9161914 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(9 years from now)

US10166206 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(9 years from now)

US10166205 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(9 years from now)

US10729667 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(9 years from now)

US10695303 SEBELA IRELAND LTD Topical compositions and methods for making and using same
Jan, 2033

(9 years from now)

Drugs and Companies using NAFTIFINE HYDROCHLORIDE ingredient

Market Authorisation Date: 27 June, 2013

Treatment: Treatment of fungal infections

Dosage: GEL;TOPICAL

How can I launch a generic of NAFTIN before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic